celecoxib has been researched along with Leukopenia in 2 studies
Leukopenia: A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000).
Excerpt | Relevance | Reference |
---|---|---|
"Celecoxib was prescribed at 400 mg twice daily beginning on day 1 for 1 year." | 2.73 | A Phase II study of acute toxicity for Celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128. ( Avizonis, V; Dicker, AP; Eifel, PJ; Fromm, M; Gaffney, DK; Greven, K; Miller, B; Ryu, J; Winter, K, 2007) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Herrera, FG | 1 |
Chan, P | 1 |
Doll, C | 1 |
Milosevic, M | 1 |
Oza, A | 1 |
Syed, A | 1 |
Pintilie, M | 1 |
Levin, W | 1 |
Manchul, L | 1 |
Fyles, A | 1 |
Gaffney, DK | 1 |
Winter, K | 1 |
Dicker, AP | 1 |
Miller, B | 1 |
Eifel, PJ | 1 |
Ryu, J | 1 |
Avizonis, V | 1 |
Fromm, M | 1 |
Greven, K | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Phase I/II Study Of COX-2 Inhibitor, CELEBREX (CELECOXIB), And Chemoradiation In Patients With Locally Advanced Cervical Cancer[NCT00023660] | Phase 1/Phase 2 | 84 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
2 trials available for celecoxib and Leukopenia
Article | Year |
---|---|
A prospective phase I-II trial of the cyclooxygenase-2 inhibitor celecoxib in patients with carcinoma of the cervix with biomarker assessment of the tumor microenvironment.
Topics: Adult; Aged; Biomarkers, Tumor; Celecoxib; Cell Hypoxia; Combined Modality Therapy; Cyclooxygenase 2 | 2007 |
A Phase II study of acute toxicity for Celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Adeno | 2007 |